

Oxford Immunotec Global PLC
Condensed consolidated statements of operations
(unaudited)

(in thousands, except share and per share data)	Three months ended December 31,		Year ended December 31,	
	2014	2013	2014	2013
Revenue				
Product	\$ 6,215	\$ 5,017	\$ 25,407	\$ 19,905
Service	5,903	5,208	24,098	18,879
Total revenue	12,118	10,225	49,505	38,784
Cost of revenue				
Product	2,418	1,708	11,225	8,475
Service	3,074	2,727	12,784	10,125
Total cost of revenue	5,492	4,435	24,009	18,600
Gross profit.....	6,626	5,790	25,496	20,184
Operating expenses:				
Research and development	2,848	563	7,033	2,146
Sales and marketing	7,111	3,713	25,487	13,270
General and administrative	3,390	3,662	14,837	12,119
Total operating expenses	13,349	7,938	47,357	27,535
Loss from operations.....	(6,723)	(2,148)	(21,861)	(7,351)
Other income (expense):				
Interest income (expense), net	52	(72)	(52)	(328)
Foreign exchange losses	(21)	(467)	(352)	(423)
Other income (expense).....	75	(584)	245	(470)
Loss before income taxes.....	(6,617)	(3,271)	(22,020)	(8,572)
Income tax expense	75	57	154	92
Net loss.....	\$ (6,692)	\$ (3,328)	\$ (22,174)	\$ (8,664)
Net loss per share attributable to ordinary shareholders— basic and diluted	\$ (0.39)	\$ (0.38)	\$ (1.28)	\$ (2.26)
Weighted-average shares used to compute net loss attributable to ordinary shareholders—basic and diluted	17,337,646	8,721,880	17,310,148	3,830,837

Note: 2013 share and per share amounts have been adjusted to reflect the Company's
1-for-6.705 reverse share split which occurred in November 2013.

Reconciliation of net loss to Adjusted EBITDA
(unaudited)

(in thousands)	Three months ended December 31,		Year ended December 31,	
	2014	2013	2014	2013
Net loss.....	\$ (6,692)	\$ (3,328)	\$ (22,174)	\$ (8,664)
Income tax expense	75	57	154	92
Interest (income) expense, net.....	(52)	72	52	328
Depreciation and amortization	503	238	1,742	1,101
EBITDA	(6,166)	(2,961)	(20,226)	(7,143)
Reconciling items:				
Share-based compensation expense.....	762	63	2,521	140
Unrealized exchange (gains) losses	(56)	346	(53)	155
Loss on change in fair value of warrants	—	279	22	279
Loss on change in fair value of derivative instrument.....	—	561	—	561
Change in fair value of contingent purchase price consideration.....	34	—	72	—
Adjusted EBITDA.....	\$ (5,426)	\$ (1,712)	\$ (17,664)	\$ (6,008)

Oxford Immunotec Global PLC
Condensed consolidated balance sheets
(unaudited)

(in thousands, except share and per share data)	December 31,	
	2014	2013
Assets		
Current assets:		
Cash and cash equivalents	\$ 50,165	\$ 76,494
Restricted cash	200	87
Accounts receivable, net	6,823	4,754
Inventory	6,425	5,450
Prepaid expenses and other	2,755	2,242
Total current assets	66,368	89,027
Restricted cash, non-current	192	362
Property and equipment, net	4,537	2,964
In-process research and development	2,399	—
Goodwill	50	—
Other intangible assets, net	273	331
Other assets	30	60
Total assets	\$ 73,849	\$ 92,744
Liabilities and shareholders' equity		
Current liabilities:		
Accounts payable	\$ 2,368	\$ 2,310
Accrued liabilities	7,070	6,936
Deferred income	1,993	1,540
Current portion of loans payable	137	170
Taxes payable	—	177
Total current liabilities	11,568	11,133
Long-term portion of loans payable	454	563
Contingent purchase price consideration	1,218	—
Other liabilities	—	296
Total liabilities	13,240	11,992
Shareholders' equity:		
Ordinary shares, £0.006705 nominal value; 40,103,528 and 25,189,285 shares authorized at December 31, 2014 and 2013, respectively, and 17,614,650 and 17,255,267 shares issued and outstanding at December 31, 2014 and 2013, respectively	192	188
Additional paid-in capital	186,816	183,967
Accumulated deficit	(121,829)	(99,655)
Accumulated other comprehensive loss	(4,570)	(3,748)
Total shareholders' equity	60,609	80,752
Total liabilities and shareholders' equity	\$ 73,849	\$ 92,744